Tibolon

Tibolon
IUPAC ime
	17-Hidroksi-7α-metil-19-nor-17α-pregn-5(10)-en-20-in-3-on
Klinički podaci
Drugs.com	Internacionalno ime leka
Kategorija trudnoće	ADEC kategorija D;
Način primene	oralno
Identifikatori
CAS broj	5630-53-5
ATC kod	G03CX01 (WHO)
PubChem	CID 444008
ChemSpider	392038
UNII	FF9X0205V2
KEGG	D01639
ChEBI	CHEBI:32223
ChEMBL	CHEMBL1558898
Sinonimi	(7α,17β)-17-etinil-17-hidroksi-7-metilestr-5(10)-en-3-one
Hemijski podaci
Formula	C21H28O2
Molarna masa	312,446 g/mol
	SMILES O=C4CCC\1=C(\C[C@H]([C@@H]2[C@@H]/1CC[C@]3([C@H]2CC[C@]3(C#C)O)C)C)C4; ;
	InChI InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1 ; Key:WZDGZWOAQTVYBX-XOINTXKNSA-N ;

Tibolon je sintetički steroidni hormonski lek, koji je u znatnoj meri neselektivan. On deluje kao agonist na svih pet tipova Tipa I steroidnog hormonskog receptora.^[1] On se prvenstveno koristi za lečenje endometrioze,^[2] kao i u terapiji zamene hormona kod žena nakon menopauze. Tibolon ima sličnu ili veću efikasnost u odnosu na starije lekove za hormonsku zamenu, ali ima sličan profil nepoželjnih efekata.^[3]^[4]^[5] On je isto tako bio istraživan kao mogući tretman za seksualnu disfunkciju žena,^[6] mada nije jasno da li koristi takve primene opravdavaju izlaganje poznatim rizicima uporebe leka.

Nepoželjna dejstva[уреди | уреди извор]

Tamoksifen, raloksifen, i tibolon korišteni za suzbijanje kancera dojke znatno redukuju invazivni kancer kor žena srednjeg i poznog doba. Međutim, oni isto tako povečavaju rizik od nepoželjnih nuspojava.^[7]

Reference[уреди | уреди извор]

^ Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). „Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites”. The Journal of Steroid Biochemistry and Molecular Biology. 116 (1-2): 8—14. PMID 19464167. doi:10.1016/j.jsbmb.2009.03.008.
^ Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A (2009). Al Kadri, Hanan, ур. „Hormone therapy for endometriosis and surgical menopause”. Cochrane Database of Systematic Reviews (Online) (1): CD005997. PMID 19160262. doi:10.1002/14651858.CD005997.pub2.
^ Lazovic G, Radivojevic U, Marinkovic J (2008). „Tibolone: the way to beat many a postmenopausal ailments”. Expert Opinion on Pharmacotherapy. 9 (6): 1039—47. PMID 18377345. doi:10.1517/14656566.9.6.1039.
^ Garefalakis M, Hickey M (2008). „Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence”. Clinical Interventions in Aging. 3 (1): 1—8. PMC 2544356 . PMID 18488873.
^ Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN (2009). „Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists”. European Journal of Gynaecological Oncology. 30 (1): 82—4. PMID 19317264.
^ Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2009 Sep 1:1-10. PMID 19731119
^ Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects Архивирано на сајту Wayback Machine (21. септембар 2012), Приступљено 11. 4. 2013.

Spoljašnje veze[уреди | уреди извор]

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[pmid19464167-1] Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). „Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites”. The Journal of Steroid Biochemistry and Molecular Biology. 116 (1-2): 8—14. PMID 19464167. doi:10.1016/j.jsbmb.2009.03.008.

[pmid19160262-2] Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A (2009). Al Kadri, Hanan, ур. „Hormone therapy for endometriosis and surgical menopause”. Cochrane Database of Systematic Reviews (Online) (1): CD005997. PMID 19160262. doi:10.1002/14651858.CD005997.pub2.

[pmid18377345-3] Lazovic G, Radivojevic U, Marinkovic J (2008). „Tibolone: the way to beat many a postmenopausal ailments”. Expert Opinion on Pharmacotherapy. 9 (6): 1039—47. PMID 18377345. doi:10.1517/14656566.9.6.1039.

[pmid18488873-4] Garefalakis M, Hickey M (2008). „Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence”. Clinical Interventions in Aging. 3 (1): 1—8. PMC 2544356 . PMID 18488873.

[pmid19317264-5] Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN (2009). „Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists”. European Journal of Gynaecological Oncology. 30 (1): 82—4. PMID 19317264.

[6] Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2009 Sep 1:1-10. PMID 19731119

[7] Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects Архивирано на сајту Wayback Machine (21. септембар 2012), Приступљено 11. 4. 2013.

[1]

[2]

[3]

[4]

[5]

[6]

[7]